EA201270445A1 - Комбинация - Google Patents

Комбинация

Info

Publication number
EA201270445A1
EA201270445A1 EA201270445A EA201270445A EA201270445A1 EA 201270445 A1 EA201270445 A1 EA 201270445A1 EA 201270445 A EA201270445 A EA 201270445A EA 201270445 A EA201270445 A EA 201270445A EA 201270445 A1 EA201270445 A1 EA 201270445A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chloro
methyl
pharmaceutically acceptable
acceptable salt
relates
Prior art date
Application number
EA201270445A
Other languages
English (en)
Other versions
EA021951B1 (ru
Inventor
Мелисса Дамбл
Тона Джилмер
Ракеш Кумар
Питер Ф. Лебовиц
Шэннон Рене Моррис
Сильви Лакерр
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201270445A1 publication Critical patent/EA201270445A1/ru
Publication of EA021951B1 publication Critical patent/EA021951B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к способу лечения рака у человека и фармацевтической комбинации, полезной для такого лечения. В частности, способ относится к способу лечения рака, который включает введение N-{3-[3-циклопропил-5-(2-фтор-4-йодфениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]фенил}ацетамида или его фармацевтически приемлемой соли, или сольвата и N-{(1S)-2-амино-1-[(3,4-дифторфенил)метил]этил}-5-хлор-4-(4-хлор-1-метил-1Н-пиразол-5-ил)-2-фуранкарбоксамида или его фармацевтически приемлемой соли нуждающемуся в этом человеку.
EA201270445A 2009-09-23 2010-09-23 Противораковая комбинация EA021951B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24501909P 2009-09-23 2009-09-23
PCT/US2010/049946 WO2011038082A1 (en) 2009-09-23 2010-09-23 Combination

Publications (2)

Publication Number Publication Date
EA201270445A1 true EA201270445A1 (ru) 2013-03-29
EA021951B1 EA021951B1 (ru) 2015-10-30

Family

ID=43796197

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270445A EA021951B1 (ru) 2009-09-23 2010-09-23 Противораковая комбинация

Country Status (14)

Country Link
US (2) US20120322817A1 (ru)
EP (1) EP2480084B1 (ru)
JP (2) JP2013505939A (ru)
KR (1) KR20120099219A (ru)
CN (1) CN102770026B (ru)
AU (1) AU2010298277B2 (ru)
BR (1) BR112012006693A2 (ru)
CA (1) CA2775124A1 (ru)
EA (1) EA021951B1 (ru)
ES (1) ES2527625T3 (ru)
IL (1) IL218797A (ru)
MX (1) MX2012003546A (ru)
WO (1) WO2011038082A1 (ru)
ZA (1) ZA201202173B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
JP2020530498A (ja) * 2017-08-11 2020-10-22 キュアマッチ インコーポレイテッドＣｕｒｅｍａｔｃｈ， Ｉｎｃ． 癌における複数の変異を標的とする薬物の組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1301472T3 (da) * 2000-07-19 2014-04-07 Warner Lambert Co Oxygenerede estere af 4-iod-phenylamino-benzhydroxamsyrer
PL1761528T3 (pl) * 2004-06-11 2008-05-30 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3821154B1 (ja) * 2005-03-16 2006-09-13 いすゞ自動車株式会社 排気ガス浄化方法及び排気ガス浄化システム
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt

Also Published As

Publication number Publication date
KR20120099219A (ko) 2012-09-07
BR112012006693A2 (pt) 2015-09-08
WO2011038082A1 (en) 2011-03-31
EP2480084A4 (en) 2013-02-20
EP2480084B1 (en) 2014-11-12
EP2480084A1 (en) 2012-08-01
JP2013505939A (ja) 2013-02-21
EA021951B1 (ru) 2015-10-30
JP2016106092A (ja) 2016-06-16
ES2527625T3 (es) 2015-01-27
CA2775124A1 (en) 2011-03-31
US20150094321A1 (en) 2015-04-02
CN102770026B (zh) 2015-04-01
AU2010298277B2 (en) 2014-07-03
IL218797A0 (en) 2012-06-28
IL218797A (en) 2014-11-30
ZA201202173B (en) 2012-11-28
CN102770026A (zh) 2012-11-07
AU2010298277A1 (en) 2012-04-19
MX2012003546A (es) 2012-09-07
US20120322817A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MY168791A (en) Carbamate compounds and of making and using same
IN2012DN06720A (ru)
EA201691695A1 (ru) Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
UA95447C2 (ru) Способ женской контрацепции
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA200970224A1 (ru) Лечение заболеваний хряща
IN2015DN01164A (ru)
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
EA201270445A1 (ru) Комбинация
EA201391027A1 (ru) Комбинация
NZ628699A (en) Process for improved opioid synthesis
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
EA201591047A1 (ru) Новая фармацевтическая композиция
IN2015DN02667A (ru)
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
EA201500882A1 (ru) Комбинация
CY1111805T1 (el) Υποκατεστημενες κινολονες ιιι

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU